Efficacy and safety of combination of radiotherapy and chemotherapy in treatment drug therapy of patients with tar-get of brain metastases origin from lung cancer

LI Wei; ZHANG Haiyan; SONG Tingting; HU Fangjuan

doi:10.3969/j.issn.1671-6450.2015.05.011

Abstract：Objective To investigate the clinical effect and safety of target drug therapy combined with synchronous radiotherapy and chemotherapy in treatment of brain metastases from lung cancer.Methods From 2010 January to 2012 June, 66 cases of brain metastases origin from lung cancer patients were enrolled, using random number table, they were di-vided into combination group and control group with 33 cases in each group, the control group treated with whole brain radio-therapy, combined with synchronous chemotherapy, combination group based on the therapy of control group, also treated with target drug therapy, long term prognosis and adverse reaction were compared between the two groups of patients.Results The short term efficacy of combined group was significantly better than the control group ( Z =-2.501, P =0.012);combi-nation groupˊs total effectiveness was 93.94%, which was higher than that of the control group(81.82%) , but the difference was not significant (χ2 =2.276, P =0.131).The combination group’s median disease free survival was 8.0 months, which was longer than 5.0 months in the control group (χ2 =10.742, P =0.001);the 2 year survival rate was 36.36%in combi-nation group, control group’s 2 years survival rate was 27.27%, 2 years survival rate revealed no significant difference be-tween the two groups of patients (χ2 =0.629, P =0.428); overall survival in the combination group showed a median of 16.0 months, which was longer than 9.0 months in the control group (χ2 =4.054, P =0.044);combination group and the control group’s incidence of adverse reaction revealed no significant differences ( P <0.05).Conclusion Patients with tar-get drug therapy combined with radiotherapy and chemotherapy has positive significance to the progression of free survival, o-verall survival and efficacy for patients with brain metastasis from lung cancer.